MedElevator
Войти в исследования PharmacoEconomics · 2026
Component Clinical and Cost Outcomes Complementing Value of Information: Case Study of a Tuberculosis Diagnostics Clinical Trial.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pei Pamela, Qoshe Livia, Florance Grady, Pandya Ankur, Weinstein Milton C, Freedberg Kenneth A, Paltiel A David, Reddy Krishna P
Аннотация
PURPOSE: Conventional value-of-information (VOI) analysis bases decisions on a composite cost-effectiveness measure that aggregates clinical and cost outcomes. We sought to highlight potentially informative tradeoffs by estimating and reporting the "disaggregated" components, allowing stakeholders-such as clinicians, patients, trial funders, policymakers, and trial networks-to identify what drives the value of additional research.
METHODS: We used a microsimulation to project the value of a hypothetical trial comparing mortality associated with different tuberculosis screening strategies among hospitalized patients with human immunodeficiency virus (HIV) in South Africa. Apart from expressing VOI as conventional, "aggregated" net monetary benefit (NMB), we assessed "disaggregated" outcomes that contribute to NMB calculations: tuberculosis cases detected, deaths, life-years, and healthcare costs associated with trial-informed decisions. We varied key parameters in probabilistic sensitivity analysis. We considered two willingness-to-pay thresholds: US $3000/year of life saved (YLS) (~50% of South Africa's per-capita gross domestic product [GDP]); and $780/YLS, the willingness-to-pay value where decision uncertainty is highest, per the baseline analysis.
RESULTS: At willingness to pay = $3000/YLS, implementing the post-trial optimal strategy would produce favorable incremental NMB ($654.3 million) and better clinical outcomes (57,000 additional tuberculosis cases detected, 16,000 fewer deaths, and 294,000 more life-years), but it would incur an additional $37.4 million in healthcare costs over 5 years. At willingness to pay = $780/YLS, implementing the post-trial optimal strategy would yield positive incremental NMB of $2.5 million while lowering healthcare costs by $11 million, but it would produce worse clinical outcomes: 18,000 fewer tuberculosis cases detected, 6,000 additional deaths, and 80,000 fewer life-years.
CONCLUSIONS: Though a trial may yield positive NMB in conventional VOI analysis owing to expected cost savings, some clinical outcomes might be unfavorable. To better inform priorities, VOI studies should include disaggregated outcomes alongside aggregated NMB.
METHODS: We used a microsimulation to project the value of a hypothetical trial comparing mortality associated with different tuberculosis screening strategies among hospitalized patients with human immunodeficiency virus (HIV) in South Africa. Apart from expressing VOI as conventional, "aggregated" net monetary benefit (NMB), we assessed "disaggregated" outcomes that contribute to NMB calculations: tuberculosis cases detected, deaths, life-years, and healthcare costs associated with trial-informed decisions. We varied key parameters in probabilistic sensitivity analysis. We considered two willingness-to-pay thresholds: US $3000/year of life saved (YLS) (~50% of South Africa's per-capita gross domestic product [GDP]); and $780/YLS, the willingness-to-pay value where decision uncertainty is highest, per the baseline analysis.
RESULTS: At willingness to pay = $3000/YLS, implementing the post-trial optimal strategy would produce favorable incremental NMB ($654.3 million) and better clinical outcomes (57,000 additional tuberculosis cases detected, 16,000 fewer deaths, and 294,000 more life-years), but it would incur an additional $37.4 million in healthcare costs over 5 years. At willingness to pay = $780/YLS, implementing the post-trial optimal strategy would yield positive incremental NMB of $2.5 million while lowering healthcare costs by $11 million, but it would produce worse clinical outcomes: 18,000 fewer tuberculosis cases detected, 6,000 additional deaths, and 80,000 fewer life-years.
CONCLUSIONS: Though a trial may yield positive NMB in conventional VOI analysis owing to expected cost savings, some clinical outcomes might be unfavorable. To better inform priorities, VOI studies should include disaggregated outcomes alongside aggregated NMB.